BACKGROUND: Despite the widespread acceptance of the 23-valent pneumococcal capsular polysaccharide vaccine (PPV), its protective effect continues to be disputed. We describe a novel approach to examine the protective effect of this vaccine. METHODS: We recorded the vaccination status of every patient for whom a culture yielded Streptococcus pneumoniae during a 4.5-year period, comparing rates of prior PPV administration in patients with (1) bacteremic pneumococcal pneumonia, (2) all-invasive pneumococcal disease, (3) nonbacteremic pneumococcal pneumonia, (4) acute exacerbation of chronic bronchitis (AECB) due to S. pneumoniae, and (5) pneumococcal colonization. The principal comparisons were with patients who had bacteremic pneumonia or any invasive pneumococcal disease and those with nonbacteremic pneumococcal pneumonia. We also compared vaccination rates in patients who had nonbacteremic pneumonia with vaccination rates in patients with AECB or pneumococcal colonization. RESULTS: The rate of prior PPV vaccination was lower among patients with bacteremic pneumococcal pneumonia (39.7%) or any invasive pneumococcal disease (38.0%) than among patients with nonbacteremic pneumonia (57.6%), AECB (60.0%), or pneumococcal colonization (57.8%). PPV conferred a 54% protection rate against bacteremic versus nonbacteremic pneumococcal pneumonia. There was no apparent protection against nonbacteremic pneumonia compared, for example, with colonized persons or with those who had AECB. CONCLUSIONS: PPV provides moderate protection against invasive pneumococcal disease but does not protect against nonbacteremic pneumococcal pneumonia. These findings suggest the importance of a continued search for a better pneumococcal vaccine.
BACKGROUND: Despite the widespread acceptance of the 23-valent pneumococcal capsular polysaccharide vaccine (PPV), its protective effect continues to be disputed. We describe a novel approach to examine the protective effect of this vaccine. METHODS: We recorded the vaccination status of every patient for whom a culture yielded Streptococcus pneumoniae during a 4.5-year period, comparing rates of prior PPV administration in patients with (1) bacteremic pneumococcal pneumonia, (2) all-invasive pneumococcal disease, (3) nonbacteremic pneumococcal pneumonia, (4) acute exacerbation of chronic bronchitis (AECB) due to S. pneumoniae, and (5) pneumococcal colonization. The principal comparisons were with patients who had bacteremic pneumonia or any invasive pneumococcal disease and those with nonbacteremic pneumococcal pneumonia. We also compared vaccination rates in patients who had nonbacteremic pneumonia with vaccination rates in patients with AECB or pneumococcal colonization. RESULTS: The rate of prior PPV vaccination was lower among patients with bacteremic pneumococcal pneumonia (39.7%) or any invasive pneumococcal disease (38.0%) than among patients with nonbacteremic pneumonia (57.6%), AECB (60.0%), or pneumococcal colonization (57.8%). PPV conferred a 54% protection rate against bacteremic versus nonbacteremic pneumococcal pneumonia. There was no apparent protection against nonbacteremic pneumonia compared, for example, with colonized persons or with those who had AECB. CONCLUSIONS:PPV provides moderate protection against invasive pneumococcal disease but does not protect against nonbacteremic pneumococcal pneumonia. These findings suggest the importance of a continued search for a better pneumococcal vaccine.
Authors: Amar Safdar; Gilhen H Rodriguez; Adriana M Rueda; William G Wierda; Alessandra Ferrajoli; Daniel M Musher; Susan O'Brien; Charles A Koller; Gerald P Bodey; Michael J Keating Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: Maria C Rodriguez-Barradas; Joseph Goulet; Sheldon Brown; Matthew Bidwell Goetz; David Rimland; Michael S Simberkoff; Kristina Crothers; Amy C Justice Journal: Clin Infect Dis Date: 2008-04-01 Impact factor: 9.079
Authors: Daniel M Musher; Adriana M Rueda; Moon H Nahm; Edward A Graviss; Maria C Rodriguez-Barradas Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Myint Tin Tin Htar; Anke L Stuurman; Germano Ferreira; Cristiano Alicino; Kaatje Bollaerts; Chiara Paganino; Ralf René Reinert; Heinz-Josef Schmitt; Cecilia Trucchi; Thomas Vestraeten; Filippo Ansaldi Journal: PLoS One Date: 2017-05-23 Impact factor: 3.240
Authors: Johanna Wennervirta; Tapani Salmi; Markku Hynynen; Arvi Yli-Hankala; Anna-Maria Koivusalo; Mark Van Gils; Reino Pöyhiä; Anne Vakkuri Journal: Intensive Care Med Date: 2006-11-08 Impact factor: 17.440